Compare BHVN & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BHVN | TSLX |
|---|---|---|
| Founded | 2013 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 2022 | 2011 |
| Metric | BHVN | TSLX |
|---|---|---|
| Price | $14.03 | $17.14 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 11 |
| Target Price | ★ $21.27 | $19.77 |
| AVG Volume (30 Days) | ★ 2.5M | 478.0K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | ★ 10.18% |
| EPS Growth | ★ 26.08 | N/A |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.82 |
| P/E Ratio | ★ N/A | $116.27 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.48 | $16.04 |
| 52 Week High | $18.57 | $23.19 |
| Indicator | BHVN | TSLX |
|---|---|---|
| Relative Strength Index (RSI) | 58.41 | 43.37 |
| Support Level | $13.56 | $16.39 |
| Resistance Level | $15.27 | $17.94 |
| Average True Range (ATR) | 0.81 | 0.40 |
| MACD | 0.32 | -0.00 |
| Stochastic Oscillator | 56.59 | 41.85 |
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder and others. Its pipeline products include: BHV-2000, BHV-7000, BHV-2100, BHV-8000, BHV-1310, BHV-1300, BHV-1400, BHV-1600, BHV-1530, and BHV-1500.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. The company partners with other companies across a variety of industries and provides creative solutions with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.